Sharing best and innovative practices

Diffusing best practices and recognising innovative steps are among the Access to Medicine Index’s mechanisms for driving change.  We go through a rigorous process to identify and validate those activities which represent either best-in-class practice or incidences where companies are trialling something unique. 57 best practices and innovations were identified in 2016.

International Society of Pharmacovigilance Special Interest Group

Bayer
Bayer co-founded an International Society of Pharmacovigilance Special Interest Group to develop and share innovative risk minimisation methods and tools.
Continue reading

New pricing policy based on an analysis of populations’ ability to pay in key out-of-pocket markets

AstraZeneca
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
Continue reading
Global Health Fellows Program

Global Health Fellows Program

Pfizer
Through the Global Health Fellows Program, Pfizer employees are seconded to organisations working in the field to improve access, quality or efficiency of health services in underserved communities.
Continue reading
Making More Health

Making More Health

Boehringer Ingelheim
Making More Health is a business incubator that aims to identify, support and scale innovative business models that address global health challenges.
Continue reading

Consideration of four socio-economic factors to set prices for essential HIV/AIDS product in multiple priority countries

Johnson & Johnson
Johnson & Johnson uses four socio-economic factors to set prices for essential HIV/AIDS products and targets 100% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
Continue reading

Clarity in approach to IP management

AstraZeneca, GSK, Merck KGaA
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
Continue reading

Global Established Products (GEP) portfolio

Pfizer
Pfizer established a governance structure to ensure a formal mechanism for strategy development, assessment and implementation regarding its established products portfolio.
Continue reading
Su-Swastha

Su-Swastha

Merck KGaA
Su-Swastha is a commercially viable, socially responsible business model implemented in rural India.
Continue reading

African Association of Essential Drugs National Purchasing Centres training partnership

Sanofi
Sanofi has a training partnership with the African Association of Essential Drugs National Purchasing Centres (ACAME).
Continue reading
Community-based Hypertension Improvement Project

Community-based Hypertension Improvement Project

Novartis
The Community-based Hypertension Improvement Project (ComHIP) is testing an innovative healthcare model for hypertension in Ghana.
Continue reading

Approach to R&D capacity building

Novartis
Novartis takes a comprehensive approach to targeting local R&D capacity building needs.
Continue reading

Coupon/Loyalty Programme

Boehringer Ingelheim
Boehringer Ingelheim is piloting the Coupon/Loyalty Programme, which targets both patients and healthcare professionals by providing points, based on patients’ healthy behaviour.
Continue reading

Regional Business Partner Compliance Pocket Guide

Gilead
The Regional Business Partner Compliance Pocket Guide is a guide to support compliance by third parties working with Gilead.
Continue reading
Africa 2020 R&D Capacity Building

Africa 2020 R&D capacity building

GSK
GSK’s Africa 2020 strategy includes a range of R&D capacity building partnerships in sub-Saharan Africa.
Continue reading
Tianjin University-AstraZeneca Joint Laboratory

Tianjin University-AstraZeneca Joint Laboratory

AstraZeneca
AstraZeneca partners with Tianjin University to improve manufacturing safety standards in China.
Continue reading

Hepatitis C virus elimination programme

Gilead
Gilead launched an innovative donation programme with the goal of eliminating hepatitis C virus in Georgia.
Continue reading

Cities Changing Diabetes

Novo Nordisk
Cities Changing Diabetes is an innovative stakeholder engagement programme, aiming to identify and address the root causes of the rise of type 2 diabetes in urban areas.
Continue reading

StartHealth investment programme

Pfizer
Pfizer is supporting StartHealth, a health technology start-up investment programme.
Continue reading
Healthy Heart Africa Capacity Building Activities

Healthy Heart Africa capacity building activities

AstraZeneca
AstraZeneca’s Healthy Heart Africa programme includes a range of capacity building activities to help reduce the burden of hypertension in Kenya.
Continue reading

Novartis Access programme

Novartis
Novartis Access is a new company-wide business model that supports access to medicine in low- and lower-middle income countries.
Continue reading
SMS For Life

SMS for Life

Novartis
Novartis’ SMS for Life programme uses mobile technology to reduce medicine stock-outs in sub-Saharan Africa.
Continue reading

EASYDAY/EASYFOOD

Sanofi
EASYDAY/EASYFOOD aims to anticipate the risk of unethical behaviour in relation to events and dining expenses.
Continue reading

Non-exclusive voluntary licensing outside of HIV/AIDS

Bristol-Myers Squibb, Gilead
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
Continue reading
Developing Country Vaccine Manufacturers Network Training Partnership

Developing Country Vaccine Manufacturers Network training partnership

Merck KGaA
Merck KGaA has a training partnership with the Developing Countries Vaccine Manufacturers Network (DCVMN).
Continue reading

Lilly Expanding Access for People (LEAP)

Eli Lilly
Lilly Expanding Access for People (LEAP) targets diabetes in the emerging middle class in China.
Continue reading

SECI model

Eisai
The SECI model (Socialization, Externalization, Combination, and Internalization) is an innovation model to create new knowledge through interactive exchange between company employees and stakeholders.
Continue reading

The Quick-Start initiative

Bristol-Myers Squibb
Bristol-Myers Squibb is involved in the launch of an innovative structured donation programme aimed at curing hepatitis C.
Continue reading

M-Tiba mobile wallet

Pfizer
Pfizer has supported the development and implementation of M-Tiba, a mobile wallet for healthcare savings and payments.
Continue reading

Permitting supply of patented products beyond the agreed licensing territory

GSK
GSK boosts the geographic scope of the dolutegravir (Tivicay®) licence beyond the stated territory by more than 30 middle-income countries.
Continue reading

PreCare

Boehringer Ingelheim
PreCare is a new business model aiming to reach low-income communities in Kenya.
Continue reading

Advisory board on climate change and health

Sanofi
Sanofi has established an advisory board to better understand the impact of climate change on health.
Continue reading

Moving projects along the pipeline

Pfizer
Pfizer has moved a high proportion of its projects from one stage of development to the next in the last two years.
Continue reading
Young Health Programme

Young Health Programme

AstraZeneca
AstraZeneca’s Young Health Programme is a philanthropic capacity building programme focused on preventing non-communicable diseases among adolescents.
Continue reading

Tuberculosis-focused capacity building

Eli Lilly
Eli Lilly is undertaking a range of capacity building projects in India focused on tuberculosis.
Continue reading

Global Health Pharma Fund Minilab

Merck KGaA
Merck KGaA supports the Global Pharma Health Fund (GPHF) Minilab, a mobile medicine authenticator.
Continue reading

Healthy Heart Africa Global Advisory Board and National Steering Committee

AstraZeneca
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.
Continue reading

Revolving door policy

GSK
GSK has introduced a revolving door policy to mitigate the risk of conflicts of interest for new employees recruited directly from the public sector.
Continue reading

Transparency on marketing activities

Merck & Co
Merck & Co., Inc. publishes payments related to marketing activities in some low- and middle-income countries.
Continue reading

Non-exclusive voluntary licensing to support affordability and supply

Gilead
Gilead’s early, systematic approach towards non-exclusive voluntary licensing helps efficient scale up and affordable supply of patented medicines in low- and middle-income countries.
Continue reading

Publishing the registration status of products, country-by-country

Gilead
Gilead publishes where it has filed for specific products to be registered, and when filings were successful.
Continue reading

BAAF Distribution Optimisation project

Novo Nordisk
Novo Nordisk is working with distributors across different countries in Africa to optimise the supply chain and reduce the price to patients of its full diabetes portfolio.
Continue reading
MVacciNation

mVacciNation

GSK
GSK’s mVacciNation programme is a mobile technology-based supply chain management capacity building programme, aiming to increase childhood immunisation in Mozambique.
Continue reading
Informed Push Model

Informed Push Model

Merck & Co
The Informed Push Model is a distribution project aiming to improve supply chains and stock management for contraceptives in Senegal.
Continue reading

Broadest consideration of socio-economic factors when setting prices for a first-line broad spectrum antibiotic across multiple priority countries*

GSK
GSK considers the most socio-economic factors when setting prices for a first-line broad-spectrum antibiotic and targets almost 90% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
Continue reading
R&D Capacity Building Model

R&D capacity building model

GSK
GSK has a comprehensive model to build local R&D capacity in response to need.
Continue reading

Malaria-focused capacity building

Novartis
Novartis is undertaking several capacity building projects focused on malaria in sub-Saharan Africa.
Continue reading

Possible partnership

Merck & Co
Merck & Co., Inc. partnered with non-government organisation (NGO) Possible to strengthen supply chains in Nepal.
Continue reading
Leprosy-focused Capacity Building

Leprosy-focused capacity building

Novartis
Novartis is undertaking a range of projects to build local capacity to address leprosy, mainly in south-east Asia.
Continue reading

Financial, Environmental and Social Profit and Loss capturing approach

Novartis
The Financial, Environmental and Social Profit and Loss (FES P&L) approach aims to measure the social and economic impact of Novartis’ social activities on local communities.
Continue reading

Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*

AstraZeneca
AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.
Continue reading

Commitment to R&D for AMR

AstraZeneca, GSK, Johnson & Johnson, Merck & Co, Merck KGaA, Novartis, Pfizer, Roche, Sanofi
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
Continue reading

Benchmarking of targets, access initiatives in line with the Sustainable Development Goals

Merck KGaA, Novo Nordisk
Merck KGaA and Novo Nordisk are realigning their access-related targets and access initiatives with the Sustainable Development Goals (SDGs).
Continue reading

Approach to collaborative R&D

Eisai
Eisai engages in collaborative R&D that addresses the needs of people in low- and middle-income countries.
Continue reading

Considering multiple local needs to facilitate rational use of products

Novartis
Novartis adapts brochures and packaging in multiple ways to facilitate rational use of products.
Continue reading

Manufacturing capacity building approach

Merck KGaA
Merck KGaA takes a comprehensive approach to building manufacturing capacity in-house and with third parties.
Continue reading

Novartis Access Strategy Framework

Novartis
The Novartis Access Strategy Framework guides the systematic and collaborative development of equitable and affordable access-solutions targeted to serve all segments of the socioeconomic pyramid.
Continue reading

SECI model

Eisai
The SECI model (Socialization, Externalization, Combination, and Internalization) is an innovation model to create new knowledge through interactive exchange between company employees and stakeholders.
Continue reading
R&D Capacity Building Model

R&D capacity building model

GSK
GSK has a comprehensive model to build local R&D capacity in response to need.
Continue reading
Africa 2020 R&D Capacity Building

Africa 2020 R&D capacity building

GSK
GSK’s Africa 2020 strategy includes a range of R&D capacity building partnerships in sub-Saharan Africa.
Continue reading

Advisory board on climate change and health

Sanofi
Sanofi has established an advisory board to better understand the impact of climate change on health.
Continue reading
Healthy Heart Africa Capacity Building Activities

Healthy Heart Africa capacity building activities

AstraZeneca
AstraZeneca’s Healthy Heart Africa programme includes a range of capacity building activities to help reduce the burden of hypertension in Kenya.
Continue reading

Lilly Expanding Access for People (LEAP)

Eli Lilly
Lilly Expanding Access for People (LEAP) targets diabetes in the emerging middle class in China.
Continue reading
Informed Push Model

Informed Push Model

Merck & Co
The Informed Push Model is a distribution project aiming to improve supply chains and stock management for contraceptives in Senegal.
Continue reading
MVacciNation

mVacciNation

GSK
GSK’s mVacciNation programme is a mobile technology-based supply chain management capacity building programme, aiming to increase childhood immunisation in Mozambique.
Continue reading

Novartis Access programme

Novartis
Novartis Access is a new company-wide business model that supports access to medicine in low- and lower-middle income countries.
Continue reading

African Association of Essential Drugs National Purchasing Centres training partnership

Sanofi
Sanofi has a training partnership with the African Association of Essential Drugs National Purchasing Centres (ACAME).
Continue reading

Possible partnership

Merck & Co
Merck & Co., Inc. partnered with non-government organisation (NGO) Possible to strengthen supply chains in Nepal.
Continue reading

M-Tiba mobile wallet

Pfizer
Pfizer has supported the development and implementation of M-Tiba, a mobile wallet for healthcare savings and payments.
Continue reading

Malaria-focused capacity building

Novartis
Novartis is undertaking several capacity building projects focused on malaria in sub-Saharan Africa.
Continue reading

New pricing policy based on an analysis of populations’ ability to pay in key out-of-pocket markets

AstraZeneca
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
Continue reading

Consideration of four socio-economic factors to set prices for essential HIV/AIDS product in multiple priority countries

Johnson & Johnson
Johnson & Johnson uses four socio-economic factors to set prices for essential HIV/AIDS products and targets 100% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
Continue reading

Regional Business Partner Compliance Pocket Guide

Gilead
The Regional Business Partner Compliance Pocket Guide is a guide to support compliance by third parties working with Gilead.
Continue reading

Transparency on marketing activities

Merck & Co
Merck & Co., Inc. publishes payments related to marketing activities in some low- and middle-income countries.
Continue reading

Novartis Access Strategy Framework

Novartis
The Novartis Access Strategy Framework guides the systematic and collaborative development of equitable and affordable access-solutions targeted to serve all segments of the socioeconomic pyramid.
Continue reading

Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*

AstraZeneca
AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.
Continue reading
SMS For Life

SMS for Life

Novartis
Novartis’ SMS for Life programme uses mobile technology to reduce medicine stock-outs in sub-Saharan Africa.
Continue reading
Tianjin University-AstraZeneca Joint Laboratory

Tianjin University-AstraZeneca Joint Laboratory

AstraZeneca
AstraZeneca partners with Tianjin University to improve manufacturing safety standards in China.
Continue reading

Benchmarking of targets, access initiatives in line with the Sustainable Development Goals

Merck KGaA, Novo Nordisk
Merck KGaA and Novo Nordisk are realigning their access-related targets and access initiatives with the Sustainable Development Goals (SDGs).
Continue reading

Healthy Heart Africa Global Advisory Board and National Steering Committee

AstraZeneca
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.
Continue reading

Tuberculosis-focused capacity building

Eli Lilly
Eli Lilly is undertaking a range of capacity building projects in India focused on tuberculosis.
Continue reading

EASYDAY/EASYFOOD

Sanofi
EASYDAY/EASYFOOD aims to anticipate the risk of unethical behaviour in relation to events and dining expenses.
Continue reading

StartHealth investment programme

Pfizer
Pfizer is supporting StartHealth, a health technology start-up investment programme.
Continue reading

Considering multiple local needs to facilitate rational use of products

Novartis
Novartis adapts brochures and packaging in multiple ways to facilitate rational use of products.
Continue reading
Community-based Hypertension Improvement Project

Community-based Hypertension Improvement Project

Novartis
The Community-based Hypertension Improvement Project (ComHIP) is testing an innovative healthcare model for hypertension in Ghana.
Continue reading

Manufacturing capacity building approach

Merck KGaA
Merck KGaA takes a comprehensive approach to building manufacturing capacity in-house and with third parties.
Continue reading

Revolving door policy

GSK
GSK has introduced a revolving door policy to mitigate the risk of conflicts of interest for new employees recruited directly from the public sector.
Continue reading
Global Health Fellows Program

Global Health Fellows Program

Pfizer
Through the Global Health Fellows Program, Pfizer employees are seconded to organisations working in the field to improve access, quality or efficiency of health services in underserved communities.
Continue reading

Financial, Environmental and Social Profit and Loss capturing approach

Novartis
The Financial, Environmental and Social Profit and Loss (FES P&L) approach aims to measure the social and economic impact of Novartis’ social activities on local communities.
Continue reading

The Quick-Start initiative

Bristol-Myers Squibb
Bristol-Myers Squibb is involved in the launch of an innovative structured donation programme aimed at curing hepatitis C.
Continue reading

Approach to collaborative R&D

Eisai
Eisai engages in collaborative R&D that addresses the needs of people in low- and middle-income countries.
Continue reading

Moving projects along the pipeline

Pfizer
Pfizer has moved a high proportion of its projects from one stage of development to the next in the last two years.
Continue reading

Coupon/Loyalty Programme

Boehringer Ingelheim
Boehringer Ingelheim is piloting the Coupon/Loyalty Programme, which targets both patients and healthcare professionals by providing points, based on patients’ healthy behaviour.
Continue reading

Approach to R&D capacity building

Novartis
Novartis takes a comprehensive approach to targeting local R&D capacity building needs.
Continue reading

Cities Changing Diabetes

Novo Nordisk
Cities Changing Diabetes is an innovative stakeholder engagement programme, aiming to identify and address the root causes of the rise of type 2 diabetes in urban areas.
Continue reading

BAAF Distribution Optimisation project

Novo Nordisk
Novo Nordisk is working with distributors across different countries in Africa to optimise the supply chain and reduce the price to patients of its full diabetes portfolio.
Continue reading
Developing Country Vaccine Manufacturers Network Training Partnership

Developing Country Vaccine Manufacturers Network training partnership

Merck KGaA
Merck KGaA has a training partnership with the Developing Countries Vaccine Manufacturers Network (DCVMN).
Continue reading

Non-exclusive voluntary licensing to support affordability and supply

Gilead
Gilead’s early, systematic approach towards non-exclusive voluntary licensing helps efficient scale up and affordable supply of patented medicines in low- and middle-income countries.
Continue reading

Hepatitis C virus elimination programme

Gilead
Gilead launched an innovative donation programme with the goal of eliminating hepatitis C virus in Georgia.
Continue reading

Global Established Products (GEP) portfolio

Pfizer
Pfizer established a governance structure to ensure a formal mechanism for strategy development, assessment and implementation regarding its established products portfolio.
Continue reading

International Society of Pharmacovigilance Special Interest Group

Bayer
Bayer co-founded an International Society of Pharmacovigilance Special Interest Group to develop and share innovative risk minimisation methods and tools.
Continue reading
Leprosy-focused Capacity Building

Leprosy-focused capacity building

Novartis
Novartis is undertaking a range of projects to build local capacity to address leprosy, mainly in south-east Asia.
Continue reading

Non-exclusive voluntary licensing outside of HIV/AIDS

Bristol-Myers Squibb, Gilead
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
Continue reading

Commitment to R&D for AMR

AstraZeneca, GSK, Johnson & Johnson, Merck & Co, Merck KGaA, Novartis, Pfizer, Roche, Sanofi
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
Continue reading

Permitting supply of patented products beyond the agreed licensing territory

GSK
GSK boosts the geographic scope of the dolutegravir (Tivicay®) licence beyond the stated territory by more than 30 middle-income countries.
Continue reading

Broadest consideration of socio-economic factors when setting prices for a first-line broad spectrum antibiotic across multiple priority countries*

GSK
GSK considers the most socio-economic factors when setting prices for a first-line broad-spectrum antibiotic and targets almost 90% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
Continue reading

Clarity in approach to IP management

AstraZeneca, GSK, Merck KGaA
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
Continue reading
Su-Swastha

Su-Swastha

Merck KGaA
Su-Swastha is a commercially viable, socially responsible business model implemented in rural India.
Continue reading

Global Health Pharma Fund Minilab

Merck KGaA
Merck KGaA supports the Global Pharma Health Fund (GPHF) Minilab, a mobile medicine authenticator.
Continue reading

Publishing the registration status of products, country-by-country

Gilead
Gilead publishes where it has filed for specific products to be registered, and when filings were successful.
Continue reading

PreCare

Boehringer Ingelheim
PreCare is a new business model aiming to reach low-income communities in Kenya.
Continue reading
Young Health Programme

Young Health Programme

AstraZeneca
AstraZeneca’s Young Health Programme is a philanthropic capacity building programme focused on preventing non-communicable diseases among adolescents.
Continue reading
Making More Health

Making More Health

Boehringer Ingelheim
Making More Health is a business incubator that aims to identify, support and scale innovative business models that address global health challenges.
Continue reading

Sign up to receive updates about our work.